Upcoming Patent Loss of Jakafi Highlights Portfolio Risks; Downgrading Incyte's Moat to None
We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...
Hosted on MSN4h
Amy Schumer Quit Ozempic After 30-Lb. Weight Loss: ‘I Was Shriveling Away'
Amy Schumer is getting candid about her unpleasant experience on the weight loss drug Ozempic. The comedian and actress, 43, ...
Blockbuster weight-loss drugs flood grey market, used without supervision: ‘This trend is triggering paralysis of gut,’ warn doctors
Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...
clinicaltrialsarena10h
Boehringer seeks approval of lung disease drug after second Phase III success
Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.
Verywell Health on MSN12h
Benadryl vs. Hydroxyzine: How Do They Compare?
Medically reviewed by Alex Yampolsky, PharmD Hydroxyzine, whose brand names include Atarax and Vistaril, and Benadryl, the ...
Medscape16h
Underfunded, Underdiagnosed, and Misunderstood: What’s Next for Bipolar Disorder
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...